Biologics open a wide range of new treatment modalities and a realistic hope for the development of novel treatments for diseases that are incurable today. NsGene offers a unique combination of novel therapeutic factors and a versatile biodelivery platform that allows the company to develop, market and sell its own biological products as well as making partnerships with the established players in the field of biologics for nervous system disorders.
With several products approaching clinical development, the value of NsGene is rapidly increasing. With its strong IPR and unique products NsGene is an attractive and interesting investment opportunity for venture capital with an interest in the growing market of biologics. While the majority of NsGene’s current investors have been actively investing in NsGene since its inception in 1999, NsGene is also open to new investors.
NsGene A/S is a public limited company founded December 8, 1999. The Company is venture financed and the total amount raised to date is DKK 259 million (~€ 35 million) in cash including a loan from Vækstfonden of DKK 20 million.
